CROSS CORRELATION STATISTICAL STUDY OF ULTRASONIC CHANGES IN CONSERVATIVE TREATMENT FOR TUBAL ECTOPIC PREGNANCY
Download as PDFVolume 1, Issue 2, Pp 19-23, 2018
Author(s)
Xiaojuan Liao, Wenhui Wang, Xinke Huang, Hanlin Shuai*
Affiliation(s)
Department of Gynaecology, the First Affiliated Hospital of Jinan University, Guangzhou, 510630 China
Corresponding Author
Hanlin Shuai
ABSTRACT
Objectives: To study the correlation between tubal ectopic pregnancy ultrasound imaging changes (mass size, type, blood flow signal, and so on) and the outcome for its conservative treatment, in order to explore the predictive value of ultrasound examination in the conservative treatment of tubal pregnancy. Methods: Ninety cases of tubal pregnancy were selected, seventy-four of which were treated conservatively by methotrexate (MTX) with Mifepristone (Ru486). In all cases, the ultrasound examination and serum β-HCG value were measured before treatment, Doppler ultrasound was performed on the 7th day of treatment, and serum β-HCG value was measured on the 4th, 7th, and 14th day of treatment. And we proceeded to analyze the correlation between the size, the type of tubal pregnancy mass, and serum β-HCG level, mass flow signal before and after treatment and the outcome of treatment. Results: Different types of masses were positively correlated with the levels of β-HCG before treatment and the different levels of Doppler ultrasound signals (r = 0.631, P < 0.05). The conservative treatment outcomes of different types of masses are different, and the conservative treatment on heterogeneous masses had the highest success rate (X2 = 24.38, P < 0.001). The size of the tubal ectopic pregnancy mass had no significant relationship to the treatment outcome (X2 = 1.83, P = 0.38). Conclusion: The ultrasound examination has significant application value in predicting the conservative treatment outcome of tubal pregnancy.
KEYWORDS
Tubal ectopic pregnancy, β-HCG, ultrasound, conservative treatment, correlation
CITE THIS PAPER
Xiaojuan Liao, Wenhui Wang, Xinke Huang, Hanlin Shuai. Cross correlation statistical study of ultrasonic changes in conservative treatment for tubal ectopic pregnancy. Acta Translational Medicine. 2018, 1(2): 19-23.
REFERENCES
[1] Barash JH, Buchanan EM, Hillson C. Diagnosis and management of ectopic pregnancy. Am Fam Physician, 2014, 90(1): 34-40.
[2] Adriana RR, Kryzia RC, Maria CRS, et al. Interstitial ectopic pregnancy in high risk maternity in the Amazon region: Case report. Eur J Obstet Gyn R B, 2018, 234: e211.
[3] Ghaneie A, Grajo JR, Derr C, Kumm TR. Unusual ectopic pregnancies: sonographic findings and implications for management. J Ultrasound Med, 2015, 34(6): 951-962.
[4] Ellaithy M, Asiri M, Rateb A, et al. Prediction of recurrent ectopic pregnancy: A five-year follow-up cohort study. Eur J Obstet Gynecol Reprod Biol, 2018, 225: 70-78.
[5] Zhang D, Shi W, Li C, et al. Risk factors for recurrent ectopic pregnancy: a case-control study. BJOG, 2016, 123(Suppl 3): 82-89.
[6] Lyu J, Ye H, Wang W, et al. Diagnosis and management of heterotopic pregnancy following embryo transfer: clinical analysis of 55 cases from a single institution. Arch Gynecol Obstet, 2017, 296(1): 85-92.
[7] Debras E, Fernandez H, Pourcelot AG, et al. Medical management of interstitial pregnancy by in situ methotrexate. J Gynecol Obstet Biol Reprod (Paris), 2016, 45(7): 673-678.
[8] Jurkovic D, Memtsa M, Sawyer E, et al. Single-dose systemic methotrexate vs expectant management for treatment of tubal ectopic pregnancy: a placebo-controlled randomized trial. Ultrasound Obstet Gynecol, 2016, 21(12): 538-544.
[9] Vázquez DD, Ríos AP, Calvo CF, et al. Mature solid tubal teratoma producing β-HCG simulating a ruptured tubal ectopic pregnancy. Eur J Obstet Gynecol Reprod Biol, 2016, 198(6): 165-166.
[10] Jeon JH, Hwang YI, Shin IH, et al. The Risk Factors and Pregnancy Outcomes of 48 Cases of Heterotopic Pregnancy from a Single Center. J Korean Med Sci, 2016, 31(7): 1094-1099.
[11] Kovaleva A, Irishina N, Pereira A, et al. Methotrexate-treated ectopic pregnancy: beta human chorionic gonadotropin serum changes as a success predictor using a mathematical model validation. Eur J Obstet Gynecol Reprod Biol, 2017, 210(8): 35-38.
[12] Wu Z, Zhang X, Xu P, Huang X. Clinical analysis of 50 patients with heterotopic pregnancy after ovulation induction or embryo transfer. Eur J Med Res, 2018, 23(1): 17.
[13] Irani M, Elias RT, Pereira N, et al. Abdominal ectopic pregnancy with undetectable serum β-human chorionic gonadotropin 9 days following blastocyst transfer. J Obstet Gynaecol Res, 2016, 42(12): 1886-1888.